These findings underscore the potential of MCT1 inhibition as a therapeutic strategy for targeting glycolytic breast cancer cells and highlight the importance of understanding the specific metabolic dependencies of cancer cells for developing targeted therapies [22]. Here, SLC16A1 is linked to breast cancer.